Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eurofins CDMO Expands Drug Product Capabilities in Canada | Contract Pharma
Breaking News

Eurofins CDMO Expands Drug Product Capabilities in Canada

14,500 sq. ft. expansion includes new development labs and GMP manufacturing suites.

Eurofins CDMO has expanded its existing drug product operation capabilities with the early 2020 completion of its new drug product development and cGMP manufacturing facility, located in Mississauga, Canada.
 
The expansion of Eurofins’ drug product operations spans 14,500 square feet. The assets include fully equipped state-of-the-art pre-formulation and formulation development laboratories, a development suite, multiple GMP manufacturing suites, clinical packaging, and warehousing. With the expansion, Eurofins CDMO can support development and clinical manufacturing of oral solid dosage forms, including highly potent APIs. The integration of drug product operations compliments Eurofins’ existing API development and manufacturing services by providing an enhanced Quick-to-Clinic drug product strategy designed to meet clients’ needs for phase I and II products.
 
The company says this complement of services offers science-driven strategies which enhance the drug product performance of APIs, from IND enabling through to late stage programs. The new drug product facility allows Eurofins CDMO to offer all drug development services under one roof, achieving enhanced science faster. 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters